Subcutaneous daratumumab with pomalidomide and dexamethasone (D-Pd) is an effective and convenient treatment for patients with relapsed or refractory multiple myeloma who have received at least one line of therapy, including lenalidomide and a proteasome inhibitor. Speaking at the 62nd ASH Annual Meeting, Professor Meletios Dimopoulos presented the findings of the phase 3 APOLLO study ...
Subcut daratumumab: reducing treatment burden in myeloma
By Mardi Chapman
10 Dec 2020